These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8067283)

  • 1. Carcinogen-DNA and protein adducts as intermediate biomarkers for human chemoprotection trials.
    Groopman JD; Roebuck BD; Kensler TW
    Adv Exp Med Biol; 1994; 354():149-60. PubMed ID: 8067283
    [No Abstract]   [Full Text] [Related]  

  • 2. Carcinogen-DNA and protein adducts: biomarkers for cohort selection and modifiable endpoints in chemoprevention trials.
    Kensler TW; Groopman JD
    J Cell Biochem Suppl; 1996; 25():85-91. PubMed ID: 9027603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein adducts in the molecular dosimetry of chemical carcinogens.
    Skipper PL; Tannenbaum SR
    Carcinogenesis; 1990 Apr; 11(4):507-18. PubMed ID: 2182215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of carcinogen-DNA and carcinogen-protein adduct biomarkers for cohort selection and as modifiable end points in chemoprevention trials.
    Kensler TW; Groopman JD; Wogan GN
    IARC Sci Publ; 1996; (139):237-48. PubMed ID: 8923034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The light at the end of the tunnel for chemical-specific biomarkers: daylight or headlight?
    Groopman JD; Kensler TW
    Carcinogenesis; 1999 Jan; 20(1):1-11. PubMed ID: 9934843
    [No Abstract]   [Full Text] [Related]  

  • 6. Transient intervention with oltipraz protects against aflatoxin-induced hepatic tumorigenesis.
    Bolton MG; Muñoz A; Jacobson LP; Groopman JD; Maxuitenko YY; Roebuck BD; Kensler TW
    Cancer Res; 1993 Aug; 53(15):3499-504. PubMed ID: 8339253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular dosimetry of urinary aflatoxin-N7-guanine and serum aflatoxin-albumin adducts predicts chemoprotection by 1,2-dithiole-3-thione in rats.
    Groopman JD; DeMatos P; Egner PA; Love-Hunt A; Kensler TW
    Carcinogenesis; 1992 Jan; 13(1):101-6. PubMed ID: 1733561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of urinary DNA adducts as markers of carcinogen exposure.
    Shuker DE; Farmer PB
    Chem Res Toxicol; 1992; 5(4):450-60. PubMed ID: 1391611
    [No Abstract]   [Full Text] [Related]  

  • 9. Molecular biomarkers for aflatoxins and their application to human cancer prevention.
    Groopman JD; Wogan GN; Roebuck BD; Kensler TW
    Cancer Res; 1994 Apr; 54(7 Suppl):1907s-1911s. PubMed ID: 8137310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular biomarkers for aflatoxins and their application to human liver cancer.
    Scholl P; Musser SM; Kensler TW; Groopman JD
    Pharmacogenetics; 1995; 5 Spec No():S171-6. PubMed ID: 7581490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA adducts of aflatoxins, sterigmatocystin and other mycotoxins.
    McConnell IR; Garner RC
    IARC Sci Publ; 1994; (125):49-55. PubMed ID: 7806340
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunocytochemical analysis of carcinogen-DNA adducts in normal and preneoplastic tissues.
    Scherer E; Bax H; van Benthem J
    Prog Histochem Cytochem; 1991; 23(1-4):77-83. PubMed ID: 1947170
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemoprotection by inducers of electrophile detoxication enzymes.
    Kensler TW; Davidson NE; Groopman JD; Roebuck BD; Prochaska HJ; Talalay P
    Basic Life Sci; 1993; 61():127-36. PubMed ID: 8304925
    [No Abstract]   [Full Text] [Related]  

  • 14. Carcinogen-nucleic acid interactions: equilibrium binding studies of aflatoxins B1 and B2 with DNA and the oligodeoxynucleotide d(ATGCAT)2.
    Stone MP; Gopalakrishnan S; Harris TM; Graves DE
    J Biomol Struct Dyn; 1988 Apr; 5(5):1025-41. PubMed ID: 3152158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprotection by natural chlorophylls in vivo: inhibition of dibenzo[a,l]pyrene-DNA adducts in rainbow trout liver.
    Harttig U; Bailey GS
    Carcinogenesis; 1998 Jul; 19(7):1323-6. PubMed ID: 9683196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The toxicology of aflatoxins as a basis for public health decisions.
    Wild CP; Turner PC
    Mutagenesis; 2002 Nov; 17(6):471-81. PubMed ID: 12435844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of aflatoxins B1 and G1 with tissues of the rat.
    Lijinsky W; Lee KY; Gallagher CH
    Cancer Res; 1970 Aug; 30(8):2280-3. PubMed ID: 5459772
    [No Abstract]   [Full Text] [Related]  

  • 18. Chemoprevention of carcinogen-DNA adducts and chronic degenerative diseases.
    Izzotti A; D'Agostini F; Bagnasco M; Scatolini L; Rovida A; Balansky RM; Cesarone CF; De Flora S
    Cancer Res; 1994 Apr; 54(7 Suppl):1994s-1998s. PubMed ID: 8137327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular dosimetry of aflatoxin DNA adducts in humans and experimental rat models.
    Groopman JD; Roebuck BD; Kensler TW
    Prog Clin Biol Res; 1992; 374():139-55. PubMed ID: 1320272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the isolated perfused rat liver to study carcinogen-DNA adduct formation from aflatoxin B1 and sterigmatocystin.
    Essigmann JM; Donahue PR; Story DL; Wogan GN; Brunengraber H
    Cancer Res; 1980 Nov; 40(11):4085-91. PubMed ID: 6781740
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.